Glucocorticoids in rheumatology: 130th anniversary of the birth of Philip Showalter Hench
https://doi.org/10.47360/1995-4484-2026-223-226
Abstract
The year 2026 marks the 130th anniversary of the birth of the eminent American rheumatologist Philip Showalter Hench, who in 1950 (along with biochemists Edward Kendall and Tadeusz Reichstein) was awarded the Nobel Prize in Physiology or Medicine “for their discoveries relating to the hormones of the adrenal cortex, their structure and biological effects”. The article summarizes data concerning the history of the study and contribution of P. Hench to the development of glucocorticoids, and examines the prospects of glucocorticoid therapy in immune-mediated rheumatic diseases.
About the Author
E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology; N.I. Pirogov Russian National Research Medical University
Russian Federation
Competing Interests:
Russian Federation
Evgeny Nasonov
115522, Moscow, Kashirskoye Highway, 34A;117997, Moscow, Ostrovitianova str., 1
Competing Interests:
Автор несет полную ответственность за предоставление окончательной версии рукописи в печать
References
1. Lloyd M. Philip Showalter Hench, 1896–1965. Rheumatology (Oxford). 2002;41(5):582-584. doi: 10.1093/rheumatology/41.5.582
2. Le Fanu J. 1949: Cortisone. In: Le Fanu J (ed). The rise and fall of modern medicine. NY:Carroll & Graff Publishers, Inc; 2000: 16-25.
3. Glyn J. The discovery and early use of cortisone. J R Soc Med. 1998;91(10):513-517. doi: 10.1177/014107689809101004
4. Hench PS. Analgesia accompanying hepatitis and jaundice in cases of chronic arthritis, fibrositis and sciatic pain. Proceedings of the Staff Meetings of the Mayo Clinic. 1933;8:433-437.
5. Selye H. A syndrome produced by diverse nocuous agents. Nature. 1936;138:32.
6. Hetenyi G Jr, Karsh J. Cortisone therapy: A challenge to academic medicine in 1949–1952. Perspect Biol Med. 1997;40(3):426-439. doi: 10.1353/pbm.1997.0006
7. Hench PS, Kendall EC, Slocumb CH, Polley HF. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch Intern Med (Chic). 1950;85(4):545-666. doi: 10.1001/archinte.1950.00230100002001
8. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bulletin of the Johns Hopkins Hospital. 1932;50:137-195.
9. The Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of Cortisone, A.C.T.H., and Other Therapeutic Measures in Chronic Rheumatic Diseases. A comparison of cortisone and aspirin in the treatment of early cases of rheumatoid arthritis; A report by the Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of Cortisone, A.C.T.H., and Other Therapeutic Measures in Chronic Rheumatic Diseases. Br Med J. 1954;1(4873):1223-1227.
10. The Joint Committee of the Medical Research Council and Nuffield Foundation. A Comparison of cortisone and aspirin in the treatment of early cases of rheumatoid arthritis; A second report by the Joint Committee of the Medical Research Council and Nuffield Foundation on clinical trials of cortisone, A.C.T.H., and other therapeutic measures in chronic rheumatic diseases. Br Med J. 1955;2(4941):695-700.
11. The Joint Committee of the Medical Research Council and Nuffield Foundation; Kellgren JH. Long-term results in early cases of rheumatoid arthritis treated with either cortisone or aspirin. Br Med J. 1957;1(5023):847-850.
12. EMPIRE Rheumatism Council. Multi-centre controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumatoid arthritis; results up to one year. Ann Rheum Dis. 1955;14(4):353-370. doi: 10.1136/ard.14.4.353
13. A comparison of prednisolone with aspirin on other analgesics in the treatment of rheumatold arthritis. Ann Rheum Dis. 1959;18(3):173-188.
14. Lundberg IE, Grundtman C, Larsson E, Klareskog L. Corticosteroids – from an idea to clinical use. Best Pract Res Clin Rheumatol. 2004;18(1):7-19. doi: 10.1016/j.berh.2003.10.003
15. Glyn JH. The discovery of cortisone: A personal memory. BMJ. 1998;317(7161):822A. doi: 10.1136/bmj.317.7161.822a
16. Hollander JL, Brown EM, Jessar RA, Brown CY. Hydrocortisone and cortisone injected into arthritic joints; comparative effects of and use of hydrocortisone as a local antiarthritic agent. J Am Med Assoc. 195;147(17):1629-1635. doi: 10.1001/jama.1951.03670340019005
17. Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17(4):233-247. doi: 10.1038/nri.2017.1
18. Nasonov EL, Chichasova NV, Kovalev VYu. Glucocorticoids in rheumatology. Moscow; 1998 (In Russ.)
19. Buttgereit F, Tam LS. Glucocorticoid treatment in patients with inflammatory rheumatic diseases: Current practice and open questions. Lancet Rheumatol. 2026;8(5):e389-e400. doi: 10.1016/S2665-9913(26)00072-X
20. Buttgereit F. Views on glucocorticoid therapy in rheumatology: The age of convergence. Nat Rev Rheumatol. 2020;16(4):239-246. doi: 10.1038/s41584-020-0370-z
21. Hardy RS, Raza K, Cooper MS. Therapeutic glucocorticoids: Mechanisms of actions in rheumatic disease. Nat Rev Rheumatol. 2020;16(3):133-144. doi: 10.1038/s41584-020-0371-y
22. Nasonov E.L. Coronavirus disease 2019 (COVID-19) and autoimmunity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(1):5-30 (In Russ.). doi: 10.47360/1995-4484-2021-5-30
23. Franco LM, Gadkari M, Howe KN, Sun J, Kardava L, Kumar P, et al. Immune regulation by glucocorticoids can be linked to cell type-dependent transcriptional responses. J Exp Med. 2019;216(2):384-406. doi: 10.1084/jem.20180595
24. Buttgereit F, Elling C, Jakob F. Design and development of glucocorticoid receptor modulators. Trends Pharmacol Sci. 2025;46(8):771-791. doi: 10.1016/j.tips.2025.06.005
25. Cummins CL, Goldstein I. New anti-inflammatory mechanism of glucocorticoids uncovered. Trends Endocrinol Metab. 2025;36(2):99-101. doi: 10.1016/j.tem.2024.08.003
26. Auger JP, Zimmermann M, Faas M, Stifel U, Chambers D, Krishnacoumar B, et al. Metabolic rewiring promotes anti-inflammatory effects of glucocorticoids. Nature. 2024;629(8010):184-192. doi: 10.1038/s41586-024-07282-7
27. Xie Y, Cheng Q, Xu ML, Xue J, Wu H, Du Y. Itaconate: A potential therapeutic strategy for autoimmune disease. Scand J Immunol. 2025;101(5):e70026. doi: 10.1111/sji.70026
28. Liu Y, Jiang X, Zhuang S, Zhu L, Zhu B, Rui K, et al. Itaconate: A key regulator of immune responses and potential therapeutic target for autoimmune and inflammatory diseases. Autoimmun Rev. 2025;24(10):103885. doi: 10.1016/j.autrev.2025.103885
Review
For citations:
Nasonov E.L. Glucocorticoids in rheumatology: 130th anniversary of the birth of Philip Showalter Hench. Rheumatology Science and Practice. 2026;64(3):223-226. (In Russ.) https://doi.org/10.47360/1995-4484-2026-223-226
Views:
59
JATS XML
Email this article 